Remove BioTech Remove Drug Development Remove Leadership
article thumbnail

Accenture Invests in QuantHealth to Accelerate Use of AI-Powered Clinical Trial Simulations to Drive Cost-Effective Drug Development

Healthcare IT Today

Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,

article thumbnail

23andMe announces major Workforce Reduction amid Financial Struggles

Digital Health Global

23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. While promising, drug development requires significant time and investment, delaying any financial returns and impacting the company’s short-term revenue.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development.

article thumbnail

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Digital Health Global

These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,

BioTech 88
article thumbnail

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Digital Health Global

Both Wellington and Forbion are visionaries and highly experienced biotech investors, and we look forward to working closely with them in our efforts to transform the gene editing landscape.” “Our billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development.